Working... Menu
Trial record 3 of 12 for:    allostim

A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00558675
Recruitment Status : Completed
First Posted : November 15, 2007
Last Update Posted : February 20, 2015
Hadassah Medical Organization
Information provided by (Responsible Party):
Immunovative Therapies, Ltd.

Brief Summary:
The purpose of this study is to determine the safety and anti-tumor effects of an experimental immunotherapy drug, called AlloStim, which is intentionally mis-matched immune cells which are designed to elicit the same anti-tumor mechanism that occurs in allogeneic bone marrow/stem cell mini-transplant (BMT) procedures, without the toxicity associated with graft vs. host disease (GVHD).

Condition or disease Intervention/treatment Phase
Hematological Malignancy Leukemia Lymphoma Multiple Myeloma Biological: AlloStim Phase 1 Phase 2

Detailed Description:

AlloStim is combination biological drug and medical device formulation consisting of allogeneic immune cells that have been expanded and differentiated ex-vivo. These cells are conjugated to monoclonal antibody coated microparticles prior to infusion. The immune cells are living CD4+ memory Th1-like T-cells (T-Stim) that are differentiated from precursors purified from normal donor blood. AlloStim is a composition of T-Stim cells conjugated to paramagnetic epoxy covered microparticles (4.5micron) with covalently bound anti-CD3/anti-CD28 monoclonal antibodies (Dynabeads® ClinExVivo™ CD3/CD28) at a 2:1 bead:cell ratio. The T-Stim cells are intentionally mismatched to the recipient.

The graft vs. tumor (GVT) effect that occurs after allogeneic bone marrow transplant (BMT) is a curative therapy for advanced hematological malignancy but the clinical application of GVT is severely limited by graft vs. host disease (GVHD) toxicity. AlloStim is designed to elicit the "mirror" of the GVT/GVHD effects in the host immune system. Rather than trying to separate these effects, we have proposed that the effects could remain associated and "mirrored" onto the host immune system creating linked host vs. tumor (HVT) and host vs. graft (HVG) effects. We hypothesized that allogeneic Th1 memory cells activated at time of infusion to produce type 1 cytokines and express CD40L would elicit HVT/HVG "mirror effects" in immunocompetent cancer patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Intentionally Mis-Matched, Allogeneic Th1 Memory Cells (AlloStim) Conjugated With CD3/CD28-coated Microbeads in Patients With Relapsed or Refractory Hematological Malignancy
Study Start Date : December 2009
Actual Primary Completion Date : December 2012
Actual Study Completion Date : March 2013

Arm Intervention/treatment
Experimental: 1
Single intravenous infusion of AlloStim
Biological: AlloStim
single intravenous infusion of 1 x 10^9 AlloStim cells

Experimental: 2
Intravenous AlloStim infusion on day 1 and day 7
Biological: AlloStim
Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7

Experimental: 3
Intravenous AlloStim infusion on day 1, day 7 and day 14
Biological: AlloStim
Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14

Experimental: 4
Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
Biological: AlloStim
Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21

Primary Outcome Measures :
  1. Determination of toxicity related to AlloStim infusion in accordance with NCI Common Toxicity Criteria v.3 [ Time Frame: Within first 48 hours post infusion, at 30 days and at 60 days post infusion ]

Secondary Outcome Measures :
  1. Evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated [ Time Frame: 30 days and 60 days post infusion and yearly thereafter ]
  2. Immunological Response [ Time Frame: 30 days, 60 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • histologically confirmed hematological malignancy
  • unresponsive to chemotherapy and/or recurrence after autologous transplant
  • adequate kidney, liver, lung and heart function

Exclusion Criteria:

  • prior allogeneic transplant
  • immunosuppressive therapy for concurrent medical condition
  • active viral infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00558675

Layout table for location information
Hadassah-Hebrew University Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Immunovative Therapies, Ltd.
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Dr. Michael Har-Noy Immunovative Therapies

Additional Information:
Layout table for additonal information
Responsible Party: Immunovative Therapies, Ltd. Identifier: NCT00558675     History of Changes
Other Study ID Numbers: ITL-001-HMC
First Posted: November 15, 2007    Key Record Dates
Last Update Posted: February 20, 2015
Last Verified: November 2012

Keywords provided by Immunovative Therapies, Ltd.:
Non-Hodgkins Lymphoma
Hodgkins Lymphoma
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Multiple Myeloma
Allogeneic Cell Therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders